33. An expression vector comprising the isolated polynucleotide of claim 32.

34. A host cell comprising the isolated polynucleotide of claim 32 or the expression vector of claim 33.

35. A method for producing the bispecific antigen binding molecule of any one of claims 1 to 31, comprising the steps of a) culturing the host cell of claim 30 under conditions suitable for the expression of the bispecific antigen binding molecule and b) recovering the bispecific antigen binding molecule.

36. A pharmaceutical composition comprising the bispecific antigen binding molecule of any one of claims 1 to 31 and a pharmaceutically acceptable carrier.

37. The bispecific antigen binding molecule of any one of claims 1 to 31 or the pharmaceutical composition of claim 36 for use as a medicament.

38. The bispecific antigen binding molecule of any one of claims 1 to 31 or the pharmaceutical composition of claim 36 for use in the treatment of a disease in an individual in need thereof.

39. The bispecific antigen binding molecule or the pharmaceutical composition of claim 38, wherein the disease is cancer.

40. Use of the bispecific antigen binding molecule of any one of claims 1 to 31 for the manufacture of a medicament for the treatment of a disease in an individual in need thereof.

~~41. A method of treating a disease in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising the bispecific antigen binding molecule of any one of claims 1 to 31 in a pharmaceutically acceptable form.~~

~~42.~~41. The use of claim 40 ~~or the method of claim 41~~, wherein said disease is cancer.